Overview

r-hLIF for Improving Embryo Implantation in IVF

Status:
Completed
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
This study was designed to obtain pilot clinical evidence of the efficacy, safety and acceptability of r-hLIF administered during the luteal phase after IVF/intra-cytoplasmic sperm injection (ICSI) and ET for improving embryo implantation in infertile women with a history of at least three implantation failures following ART. Based on LIF expression patterns and experimental data from animal research a role of LIF in embryo implantation is anticipated.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany